NEW YORK, June 6, 2026, 17:03 (EDT)
Eli Lilly shares finished the week at a record high close, gaining 0.6% Friday at $1,131.42. On Saturday, the company put out late-stage results showing its retatrutide injection, still experimental, cut obstructive sleep apnea severity by 60.6% and reduced knee osteoarthritis pain by as much as 73.1% in obese adults.
Monday’s open carries weight for Lilly. The stock ended up around 2.4% for the week, closing at $1,105.00 on May 29, but the broader market sold off late Friday. Next up is the reaction to fresh data, which may show if investors still want to push the top obesity play higher.
NYSE is closed for the weekend. Regular trading goes from 9:30 a.m. to 4 p.m. Eastern time. The next market holiday in 2026 is Juneteenth, Friday, June 19. Not Monday.
Retatrutide, called a “triple agonist,” hits three hormone receptors—GIP, GLP-1 and glucagon—linked to appetite, blood sugar and energy use. Lilly says the drug is still experimental, not cleared by regulators, and is now in Phase 3 testing, the big late-stage trials drugmakers want before filing for approval. Lilly
Lilly picks up big numbers as it heads into 2026. The company’s diabetes drug Mounjaro and obesity drug Zepbound drove most of the gains: first-quarter revenue climbed 56% to $19.8 billion. Mounjaro sales soared 125% to $8.7 billion. Zepbound was up 80% at $4.16 billion. Lilly now sees 2026 revenue coming in at $82 billion to $85 billion. “2026 is off to a strong start,” CEO David Ricks said in April. Eli Lilly and Company
The stock managed to stay strong even as the market tumbled on Friday. The S&P 500 dropped 2.64%, the Dow lost 1.35% and the Nasdaq shed 4.18%, with hotter U.S. jobs numbers pushing up rate fears and chip stocks taking a hit. “After the record run we’ve seen the last nine weeks in equities, specifically tech and semiconductors, the dam just broke today,” said Ryan Detrick, chief market strategist at Carson Group. Reuters
Lilly still faces competition. Roche said Friday its enicepatide injection led patients to lose 22.7% of body weight over 48 weeks in a phase 2 trial. Manu Chakravarthy, who heads cardiovascular, renal and metabolism product development at Roche, said the weight-loss trend showed “no hint of any plateau.” Novo Nordisk stays out in front with Wegovy and its follow-up drugs, keeping up the pressure on Lilly’s top spot. Reuters
The bullish pitch for the stock is still shaky. Retatrutide isn’t on the market yet. Safety, drop-outs, and possible pricing or insurance pushback on GLP-1 drugs could swing sales numbers fast. Manufacturing could be a problem too. Lilly said this week it will cut its planned €2.3 billion German spend in half. CEO Ricks told Handelsblatt, “Europe isn’t completely off the table, but the U.S. makes the most sense.” Reuters
Lilly heads into the week trading on pipeline hopes, not just one data release. The market has backed the stock for growth and the potential of its drugs beyond Zepbound, but its price skews high. Saturday’s retatrutide update is next, and traders will watch if it keeps excitement once rates, weakness in big tech, and competitor news pop up again.
Related articles: NYSE:LLY
